Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

BACKGROUND: This study evaluated the safety and immune responses to an autologous dendritic cell vaccine pulsed with class I peptides from tumor-associated antigens (TAA) expressed on gliomas and overexpressed in their cancer stem cell population (ICT-107). METHODS: TAA epitopes included HER2, TRP-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Phuphanich, Surasak, Wheeler, Christopher J., Rudnick, Jeremy D., Mazer, Mia, Wang, HongQian, Nuño, Miriam A., Richardson, Jaime E., Fan, Xuemo, Ji, Jianfei, Chu, Ray M., Bender, James G., Hawkins, Elma S., Patil, Chirag G., Black, Keith L., Yu, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541928/
https://www.ncbi.nlm.nih.gov/pubmed/22847020
http://dx.doi.org/10.1007/s00262-012-1319-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541928/
https://www.ncbi.nlm.nih.gov/pubmed/22847020
http://dx.doi.org/10.1007/s00262-012-1319-0

Ejemplares similares